Literature DB >> 20020092

[Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy].

K-F Bodmann1.   

Abstract

Intra-abdominal infections are generally the result of invasion and multiplication of enteric bacteria in the wall of a hollow viscus within the abdomen to produce peritonitis or abscess. When the infection extends into the peritoneal cavity or another normally sterile region of the abdominal cavity, the infection is described as a "complicated" intra-abdominal infection. Treatment of patients with complicated intra-abdominal infections involves antimicrobial therapy, generally in conjunction with an appropriate and timely surgical source control. Nearly all intra-abdominal infections are caused by multiple microorganisms that constitute the intestinal flora (aerobes and facultative and obligate anaerobes, with Enterobacteriaceae, enterococci and Bacteroides fragilis isolated most frequently). The emergence of drug resistance (e.g. ESBL-producing Enterobacteriaceae or resistant enterococci and staphylococci) poses a substantial threat to patients with surgical infections. Especially in patients with nosocomially acquired infections inadequate empiric antibiotic treatment is associated with treatment failure and death. In patients at risk broader spectrum antibiotic regimens with coverage of resistant Gram-negative bacilli and anaerobes and Gram-positive bacteria such as enterococci (including VRE) and staphylococci should be considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20020092     DOI: 10.1007/s00104-009-1822-9

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  44 in total

Review 1.  Minimising antibiotic resistance.

Authors:  David M Livermore
Journal:  Lancet Infect Dis       Date:  2005-07       Impact factor: 25.071

Review 2.  Tigecycline and the need for a new broad-spectrum antibiotic class.

Authors:  Mark H Wilcox
Journal:  Surg Infect (Larchmt)       Date:  2006-02       Impact factor: 2.150

3.  [Treatment of intra-abdominal infections with beta-lactam antibiotics. Results of some controlled prospective studies].

Authors:  H R Gonzenbach
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.

Authors:  Mark A Malangoni; James Song; Janet Herrington; Shurjeel Choudhri; Peter Pertel
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

5.  A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

Authors:  P S Barie; S B Vogel; E P Dellinger; O D Rotstein; J S Solomkin; J Y Yang; T F Baumgartner
Journal:  Arch Surg       Date:  1997-12

6.  Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS).

Authors:  P Gastmeier; D Sohr; C Geffers; M Behnke; F Daschner; H Rüden
Journal:  Infection       Date:  2005-04       Impact factor: 3.553

7.  A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections.

Authors:  M H Angerås; N Darle; K Hamnström; M Ekelund; L Engström; J Takala; A Viste; J B Holme
Journal:  Scand J Infect Dis       Date:  1996

8.  Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery.

Authors:  K Krobot; D Yin; Q Zhang; S Sen; A Altendorf-Hofmann; J Scheele; W Sendt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-21       Impact factor: 3.267

9.  Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Authors:  C Jaccard; N Troillet; S Harbarth; G Zanetti; D Aymon; R Schneider; R Chiolero; B Ricou; J Romand; O Huber; P Ambrosetti; G Praz; D Lew; J Bille; M P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.

Authors:  R J Burnett; D C Haverstock; E P Dellinger; H H Reinhart; J M Bohnen; O D Rotstein; S B Vogel; J S Solomkin
Journal:  Surgery       Date:  1995-10       Impact factor: 3.982

View more
  6 in total

1.  Bad bacteria in acute appendicitis: rare but relevant.

Authors:  Alexander Reinisch; Patrizia Malkomes; Nils Habbe; Wolf Otto Bechstein; Juliane Liese
Journal:  Int J Colorectal Dis       Date:  2017-07-15       Impact factor: 2.571

2.  Damage control surgery in perforated diverticulitis: ongoing peritonitis at second surgery predicts a worse outcome.

Authors:  M A Sohn; A Agha; P Steiner; A Hochrein; M Komm; R Ruppert; P Ritschl; F Aigner; I Iesalnieks
Journal:  Int J Colorectal Dis       Date:  2018-03-13       Impact factor: 2.571

Review 3.  [Enterococci and surgical site infections : Causal agent or harmless commensals?]

Authors:  J Pochhammer; A Kramer; M Schäffer
Journal:  Chirurg       Date:  2017-05       Impact factor: 0.955

Review 4.  Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria.

Authors:  T Herzog; A M Chromik; Waldemar Uhl
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

Review 5.  Perioperative Antibiotic Prophylaxis and Antimicrobial Therapy of Intra-Abdominal Infections.

Authors:  Stefan Hagel; Hubert Scheuerlein
Journal:  Viszeralmedizin       Date:  2014-10-06

6.  Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome.

Authors:  Jan De Waele; Jeffrey Lipman; Yasser Sakr; John C Marshall; Philippe Vanhems; Casiano Barrera Groba; Marc Leone; Jean-Louis Vincent
Journal:  BMC Infect Dis       Date:  2014-07-29       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.